| Cindy Codispoti, DO | |
|
57 Us Highway 46, Hackettstown, NJ 07840-2695 | |
| (908) 441-7201 | |
| (908) 441-1292 |
| Full Name | Cindy Codispoti |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 24 Years |
| Location | 57 Us Highway 46, Hackettstown, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366414427 | NPI | - | NPPES |
| 0431451 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 25MB09509700 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackettstown Medical Center | Hackettstown, NJ | Hospital |
| Morristown Medical Center | Morristown, NJ | Hospital |
| Newton Medical Center | Newton, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Practice Associates Medical Group | 5890703177 | 1116 |
| Cardiovascular Health Consultants, P.a. | 8325934706 | 106 |
News Archive
The SPR Center of Excellence is based in Dijon, France. Inventiva's existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva's current service offering.
According to the Australian Medical Association (AMA) every rural GP and specialist should be paid tens of thousands of dollars per year in extra incentives to encourage more to commit to country practice, warning that "urgent intervention" is required to tackle a workforce crisis.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission.
› Verified 5 days ago
| Entity Name | Cardiovascular Health Consultants, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437291739 PECOS PAC ID: 8325934706 Enrollment ID: O20040224000028 |
News Archive
The SPR Center of Excellence is based in Dijon, France. Inventiva's existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva's current service offering.
According to the Australian Medical Association (AMA) every rural GP and specialist should be paid tens of thousands of dollars per year in extra incentives to encourage more to commit to country practice, warning that "urgent intervention" is required to tackle a workforce crisis.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission.
› Verified 5 days ago
| Entity Name | Practice Associates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427016385 PECOS PAC ID: 5890703177 Enrollment ID: O20060330000690 |
News Archive
The SPR Center of Excellence is based in Dijon, France. Inventiva's existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva's current service offering.
According to the Australian Medical Association (AMA) every rural GP and specialist should be paid tens of thousands of dollars per year in extra incentives to encourage more to commit to country practice, warning that "urgent intervention" is required to tackle a workforce crisis.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cindy Codispoti, DO Po Box 416457, Boston, MA 02241-6457 Ph: (844) 362-1735 | Cindy Codispoti, DO 57 Us Highway 46, Hackettstown, NJ 07840-2695 Ph: (908) 441-7201 |
News Archive
The SPR Center of Excellence is based in Dijon, France. Inventiva's existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva's current service offering.
According to the Australian Medical Association (AMA) every rural GP and specialist should be paid tens of thousands of dollars per year in extra incentives to encourage more to commit to country practice, warning that "urgent intervention" is required to tackle a workforce crisis.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission.
› Verified 5 days ago
Parminderjeet S. Sandhu, Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 137 Mountain Ave, Hackettstown, NJ 07840 Phone: 908-852-1887 | |
Dr. Lillian Johanna Theune, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 657 Willow Grove Street,, Suite 401, Hackettstown, NJ 07840 Phone: 908-850-7800 Fax: 908-850-7802 | |
Dr. Hassan Malik, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 651 Willow Grove St, Hackettstown, NJ 07840 Phone: 908-441-1161 Fax: 908-441-1152 | |
Dr. Monisha Singhal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 137 Mountain Ave, Hackettstown, NJ 07840 Phone: 908-852-1887 Fax: 908-852-0614 | |
Dr. Anirudh Khanna, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 254b Mountain Ave Ste 203, Hackettstown, NJ 07840 Phone: 908-452-5642 | |
Dr. Sanjay Kavathia, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 616 Willow Grove St, Unit 1a, Hackettstown, NJ 07840 Phone: 908-852-8484 Fax: 908-852-4197 | |
Syed Mohsin Raza, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 117 Seber Rd, Doctors Park 2b, Hackettstown, NJ 07840 Phone: 908-684-0684 |